Skip to main content
SpringerLink
Log in

Biomarker in der Onkologie

Diagnostik, Staging, Prognoseabschätzung und Therapie

  • CME · TOPIC · biomarker
  • Published:
best practice onkologie Aims and scope

Grundlagenforschung und translationale Forschung in der Onkologie konnten in den letzten Jahren eine Reihe von Biomarker identifizieren, die für Diagnostik, Staging, Prognoseabschätzung und als Ansatzpunkte für individualisierte Therapien potentiellen klinischen Wert haben. Einige dieser Marker sind bereits seit Jahren in die klinische Praxis eingeführt, andere werden derzeit im Rahmen wissenschaftlicher Programme an spezialisierten Krebszentren in der Praxis erprobt. Dieser Beitrag gibt einen Überblick klinisch etablierter Biomarker und einen Ausblick auf ausgewählte Kandidaten, die an der Schwelle zur breiten Anwendung stehen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733–2743

    Article  PubMed  CAS  Google Scholar 

  2. Press MF, Pike MC, Hung G et al. (1994) Amplification and overexpression of HER-2/neu in carcinomas of thesalivary gland: correlation with poor prognosis. Cancer Res, 54: 5675–5682

    PubMed  CAS  Google Scholar 

  3. Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353: 1673–1684

    Article  PubMed  CAS  Google Scholar 

  4. MacGregor JI, JordanVC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev, 50: 151–196

    PubMed  CAS  Google Scholar 

  5. Bonneterre J, Thurlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol, 18: 3748–3757

    PubMed  CAS  Google Scholar 

  6. Rhodes A, Jasani B, Barnes DM et al. (2000) Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol, 53: 125–130

    Article  PubMed  CAS  Google Scholar 

  7. Habel LA, Shak S, Jacobs MK et al. (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res, 8: R25

    Article  PubMed  CAS  Google Scholar 

  8. Paik S, Shak S, Tang G et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med, 351: 2817–2826

    Article  PubMed  CAS  Google Scholar 

  9. Wolff AC, Hammond ME, Schwartz JN et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 131: 18–43

    PubMed  CAS  Google Scholar 

  10. Faratian D, Bartlett J (2008) Predictive markers in breast cancer – the future. Histopathology, 52: 91–98

    PubMed  CAS  Google Scholar 

  11. Pritchard KI, Messersmith H, Elavathil L et al. (2008) HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol, 26: 736–744

    Article  PubMed  CAS  Google Scholar 

  12. Knoop AS, Knudsen H, Balslev E et al. (2005) Rretrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol, 23:

  13. Tanner M, Jarvinen P, Isola J et al. (2001) Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res, 61: 5345–5348

    PubMed  CAS  Google Scholar 

  14. Nielsen KV, Ejlertsen B, Moller S et al. (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol, 47: 725–734

    Article  PubMed  CAS  Google Scholar 

  15. Tanner M, Isola J, Wiklund T et al. (2006) Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol, 24: 2428–2436

    Article  PubMed  CAS  Google Scholar 

  16. Sparano JA (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer , 7: 347–350

    Article  PubMed  Google Scholar 

  17. Goldstein LJ, Gray R, Badve S et al. (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol , 26: 4063–4071

    Article  PubMed  Google Scholar 

  18. Vijver MJ van de, He YD, Veer LJ van’t et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med, 347: 1999–2009

    Article  PubMed  Google Scholar 

  19. Veer LJ van’t, Dai H, Vijver MJ van de et al. (2002) Geneexpression profiling predicts clinical outcome of breast cancer. Nature, 415: 530–536

    Article  Google Scholar 

  20. Buyse M, Loi S, Veer L van’t et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst, 98: 1183–1192

    Article  PubMed  CAS  Google Scholar 

  21. Foekens JA, Atkins D, Zhang Y et al. (2006) Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol, 24: 1665–1671

    Article  PubMed  CAS  Google Scholar 

  22. Wang Y, Klijn JG, Zhang Y et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 365: 671–679

    PubMed  CAS  Google Scholar 

  23. Druker BJ, Talpaz M, Resta DJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344: 1031–1037

    Article  PubMed  CAS  Google Scholar 

  24. Kantarjian H, Talpaz M, Estey E et al (1994) What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia? Am J Med, 96: 133–138

    Article  PubMed  CAS  Google Scholar 

  25. Kurzrock R, Blick MB, Talpaz M et al. (1986) Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. Ann Intern Med, 105: 673–679

    PubMed  CAS  Google Scholar 

  26. Shtalrid M, Talpaz M, Blick M et al. (1988) Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J Clin Oncol, 6: 1569–1575

    PubMed  CAS  Google Scholar 

  27. Kurzrock R, Bueso-Ramos CE, Kantarjian H et al. (2001) BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol, 19: 2915–2926

    PubMed  CAS  Google Scholar 

  28. Kurzrock R, Kantarjian HM, Shtalrid M et al. (1990) Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood, 75: 445–452

    PubMed  CAS  Google Scholar 

  29. Kantarjian H, Sawyers C, Hochhaus A et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 346: 645–652

    Article  PubMed  CAS  Google Scholar 

  30. Kantarjian HM, O’Brien S, Cortes J et al. (2003) Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer, 98: 2636–2642

    Article  PubMed  CAS  Google Scholar 

  31. Kantarjian HM, O’Brien S, Cortes JE et al. (2002) Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 100: 1590–1595

    PubMed  CAS  Google Scholar 

  32. Reed SD, Anstrom KJ, Li Y, Schulman KA (2008) Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics, 26: 435–446

    Article  PubMed  CAS  Google Scholar 

  33. Reed SD, Anstrom KJ, Ludmer JA et al. (2004) Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 101: 2574–2583

    Article  PubMed  Google Scholar 

  34. Kantarjian H, Giles F, Wunderle L et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354: 2542–2551

    Article  PubMed  Google Scholar 

  35. Talpaz M, Shah NP, Kantarjian H et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med , 354: 2531–2541

    Article  PubMed  CAS  Google Scholar 

  36. Burger H, den Bakker MA, Kros JM et al. (2005) Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther, 4: 1270–1274

    PubMed  CAS  Google Scholar 

  37. Braconi C, Bracci R, Cellerino R (2008) Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets, 8: 359–366

    Article  PubMed  CAS  Google Scholar 

  38. Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med, 319: 525–532

    PubMed  CAS  Google Scholar 

  39. Kastrinos F, Syngal S (2007) Recently identified colon cancer predispositions: MYH and MSH6 mutations. Semin Oncol, 34: 418–424

    Article  PubMed  CAS  Google Scholar 

  40. Wang L, Baudhuin LM, Boardman LA et al. (2004) MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology, 127: 9-16

    Article  PubMed  CAS  Google Scholar 

  41. Nielsen M, Franken PF, Reinards TH et al. (2005) Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet, 42: e54

    Article  PubMed  CAS  Google Scholar 

  42. Burt RW (2000) Colon cancer screening. Gastroenterology, 119: 837–853

    Article  PubMed  CAS  Google Scholar 

  43. Lichtenstein P, Holm NV, Verkasalo PK et al. (2000) Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N EnglJ Med, 343: 78–85

    Article  CAS  Google Scholar 

  44. Ribic CM, Sargent DJ, Moore MJ et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med, 349: 247–257

    Article  PubMed  CAS  Google Scholar 

  45. Milano G, Etienne MC, Pierrefite V et al. (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer, 79: 627–630

    Article  PubMed  CAS  Google Scholar 

  46. Ando Y, Saka H, Ando M et al. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res, 60: 6921–6926

    PubMed  CAS  Google Scholar 

  47. Lord RV, Brabender J, Gandara D et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8: 2286–2291

    PubMed  CAS  Google Scholar 

  48. Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351: 337–345

    Article  PubMed  CAS  Google Scholar 

  49. Personeni N, Fieuws S, Piessevaux H et al. (2008) Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res, 14: 5869–5876

    Article  PubMed  CAS  Google Scholar 

  50. Lievre A, Bachet JB, Boige V et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 26: 374–379

    Article  PubMed  CAS  Google Scholar 

  51. Maheswaran S, Sequist LV, Nagrath S et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med, 359: 366–377

    Article  PubMed  CAS  Google Scholar 

  52. Cobo M, Isla D, Massuti B et al. (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol, 25: 2747–2754

    Article  PubMed  CAS  Google Scholar 

  53. Olaussen KA, Dunant A, Fouret P et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355: 983–991

    Article  PubMed  CAS  Google Scholar 

  54. Bepler G, Kusmartseva I, Sharma S et al. (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol, 24: 4731–4737

    Article  PubMed  CAS  Google Scholar 

  55. Simon G, Sharma A, Li X et al. (2007) Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol, 25: 2741–2746

    Article  PubMed  CAS  Google Scholar 

  56. Monzo M, Rosell R, Sanchez JJ et al. (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol, 17: 1786–1793

    PubMed  CAS  Google Scholar 

  57. Cappuzzo F, Ligorio C, Janne PA et al. (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol, 25: 2248–2255

    Article  PubMed  CAS  Google Scholar 

  58. Han SW, Kim TY, Jeon YK et al. (2006) Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res, 12: 2538–2544

    Article  PubMed  CAS  Google Scholar 

  59. Mounawar M, Mukeria A, Le Calvez F et al. (2007) Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res, 67: 5667–5672

    Article  PubMed  CAS  Google Scholar 

  60. Belani CP, Schreeder MT, Steis RG et al. (2008) Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer, 113: 2512–2517

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany

    A.-C. Hoffmann &  M. Schuler

  2. Innere Klinik (Tumorforschung) , Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Germany

    A.-C. Hoffmann

  3. Innere Klinik (Tumorforschung) , Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Germany

    M. Schuler

Authors
  1. A.-C. Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to A.-C. Hoffmann or M. Schuler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffmann, AC., Schuler, M. Biomarker in der Onkologie. best practice onkologie 3, 48–58 (2008). https://doi.org/10.1007/s11654-008-0092-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-008-0092-1

Search

Navigation